Show simple item record

dc.contributor.authorRescigno, Pen_US
dc.contributor.authorde Bono, JSen_US
dc.date.accessioned2019-05-01T13:50:46Z
dc.date.issued2019-02en_US
dc.identifier.citationNature reviews. Urology, 2019, 16 (2), pp. 69 - 70en_US
dc.identifier.issn1759-4812en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3214
dc.identifier.eissn1759-4820en_US
dc.identifier.doi10.1038/s41585-018-0121-yen_US
dc.formatPrinten_US
dc.format.extent69 - 70en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
dc.subjectHumansen_US
dc.subjectProstatic Neoplasmsen_US
dc.subjectImmunotherapyen_US
dc.subjectMaleen_US
dc.titleImmunotherapy for lethal prostate cancer.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1038/s41585-018-0121-yen_US
rioxxterms.licenseref.startdate2019-02en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfNature reviews. Urologyen_US
pubs.issue2en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublisheden_US
pubs.volume16en_US
pubs.embargo.termsNot knownen_US
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
dc.contributor.icrauthorDe Bono, Johannen_US
dc.contributor.icrauthorRescigno, Pasqualeen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record